(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Uveal Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 160 (planned)
- Started
- Jul 3, 2023
- Main results expected
- Apr 30, 2027
- Fully finished
- Apr 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Adverse Events (AEs) and significant laboratory abnormalities
Measured over: from first dose to 28 days after last dose of therapy, approximately 18 months
Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation
Measured over: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose
Measured over: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteria
Measured over: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05907954 · record last updated 2026-03-16 · checked 2026-11-09 15:36 UTC